Investigating the Effectiveness of Ceragenins against Acinetobacter baumannii to Develop New Antimicrobial and Anti-Adhesive Strategies.
Maciej KarasińskiUrszula WnorowskaTamara DanilukPiotr DeptułaMilena ŁuckiewiczPaulina PaprockaBonita DurnaśKarol SkłodowskiBeata SawczukPaul B SavageEwelina PiktelRobert BuckiPublished in: International journal of molecular sciences (2024)
A growing body of experimental data indicates that ceragenins (CSAs), which mimic the physicochemical properties of the host's cationic antimicrobial peptide, hold promise for the development of a new group of broad-spectrum antimicrobials. Here, using a set of in vivo experiments, we assessed the potential of ceragenins in the eradication of an important etiological agent of nosocomial infections, Acinetobacter baumannii . Assessment of the bactericidal effect of ceragenins CSA-13, CSA-44, and CSA-131 on clinical isolates of A. baumannii ( n = 65) and their effectiveness against bacterial cells embedded in the biofilm matrix after biofilm growth on abiotic surfaces showed a strong bactericidal effect of the tested molecules regardless of bacterial growth pattern. AFM assessment of bacterial cell topography, bacterial cell stiffness, and adhesion showed significant membrane breakdown and rheological changes, indicating the ability of ceragenins to target surface structures of A. baumannii cells. In the cell culture of A549 lung epithelial cells, ceragenin CSA-13 had the ability to inhibit bacterial adhesion to host cells, suggesting that it interferes with the mechanism of bacterial cell invasion. These findings highlight the potential of ceragenins as therapeutic agents in the development of antimicrobial strategies against bacterial infections caused by A. baumannii .
Keyphrases
- acinetobacter baumannii
- pseudomonas aeruginosa
- induced apoptosis
- multidrug resistant
- drug resistant
- staphylococcus aureus
- biofilm formation
- cell cycle arrest
- randomized controlled trial
- systematic review
- escherichia coli
- cell death
- cell therapy
- machine learning
- candida albicans
- big data
- mesenchymal stem cells
- risk assessment
- klebsiella pneumoniae
- bone marrow
- electronic health record
- pi k akt
- transcription factor
- artificial intelligence